HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback